Q-omics provides the consensus-scored CCDC180 profile across patient tissues and cancer cell-line models. CCDC180 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCDC180 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, CCDC180 RNA expression shows 19,706 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUAD, and UVM as cancer lineages where CCDC180 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC180 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC180 survival associations across molecular data types. CCDC180 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC180 RNA expression–survival associations across cancer types. High CCDC180 expression shows unfavorable associations in ACC and PRAD, but favorable associations in HNSC, PAAD, CESC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for CCDC180 RNA expression.
This table summarizes CCDC180 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC180. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC180 shows lower tumor expression in LUAD, LUSC, BRCA, BLCA and THCA and higher tumor expression in LIHC. The LUAD box plot shows higher CCDC180 RNA expression in normal versus tumor tissue (log2 FC = −0.315, t-test p = .001).
This table shows molecular features associated with CCDC180 in patient tissues and cancer cell lines. In patient samples, CCDC180 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC180 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
